Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer

被引:0
|
作者
Capuozzo, Maurizio [1 ]
Santorsola, Mariachiara [2 ]
Ianniello, Monica [3 ]
Ferrara, Francesco [1 ]
Zovi, Andrea [4 ]
Petrillo, Nadia [3 ]
Castiello, Rosa [3 ]
Fantuz, Maria Rosaria [3 ]
Ottaiano, Alessandro [2 ]
Savarese, Giovanni [3 ]
机构
[1] ASL Naples 3, Coordinamento Farmaceut, I-80056 Ercolano, Italy
[2] IRCCS G Pascale, Ist Nazl Tumori Napoli, Via M Semmola, I-80131 Naples, Italy
[3] Ctr Polidiagnost Strumentale Srl, AMES, Via Padre Carmine Fico 24, I-80013 Casalnuovo Di Napoli, Italy
[4] Minist Hlth, Viale Giorgio Ribotta 5, I-00144 Rome, Italy
关键词
prostate cancer; androgen-deprivation therapy; immunotherapy; PARP inhibitors; precision medicine; PHASE-III TRIAL; SIPULEUCEL-T; DOUBLE-BLIND; PLUS STANDARD; OPEN-LABEL; CASTRATION; IPILIMUMAB; IMMUNOTHERAPY; ENZALUTAMIDE; MULTICENTER;
D O I
10.3390/diseases12050087
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prostate cancer, a prevalent malignancy affecting the prostate gland, is a significant global health concern. Androgen-deprivation therapy (ADT) has proven effective in controlling advanced disease, with over 50% of patients surviving at the 10-year mark. However, a diverse spectrum of responses exists, and resistance to ADT may emerge over time. This underscores the need to explore innovative treatment strategies for effectively managing prostate cancer progression. Ongoing research endeavors persist in unraveling the complexity of prostate cancer and fostering the development of biologic and innovative approaches, including immunotherapies and targeted therapies. This review aims to provide a valuable synthesis of the dynamic landscape of emerging drug modalities in this context. Interestingly, the complexities posed by prostate cancer not only present a formidable challenge but also serve as a model and an opportunity for translational research and innovative therapies in the field of oncology.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] TREATMENT OF ADVANCED PROSTATE-CANCER
    RASMUSSEN, F
    HORMONE RESEARCH, 1989, 32 : 47 - 49
  • [32] Multimodality treatment in advanced prostate cancer
    Heidenreich, A
    EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (03) : 51 - 57
  • [33] TREATMENT OF ADVANCED PROSTATE-CANCER
    LYNCH, JH
    JOURNAL OF FAMILY PRACTICE, 1993, 37 (05): : 488 - 494
  • [34] Comparison of the outcomes of various radiation treatment modalities for prostate cancer
    Wong, W. W.
    Schild, S. E.
    Vora, S. A.
    Ezzell, G. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S176 - S176
  • [35] Racial variations in the use of specific prostate cancer treatment modalities
    Underwood, W
    Copeland, L
    Elshaikh, M
    Penner, L
    Jackson, J
    GERONTOLOGIST, 2005, 45 : 125 - 126
  • [36] Patient reported outcomes among treatment modalities for prostate cancer
    Johnson, Matthew E.
    Zaorsky, Nicholas G.
    Martin, Jeffrey M.
    Ruth, Karen
    Greenberg, Richard E.
    Uzzo, Robert G.
    Hayes, Shelly B.
    Smaldone, Marc C.
    Kutikov, Alexander
    Viterbo, Rosalia
    Chen, David Y. T.
    Hallman, Mark A.
    Sobczak, Mark L.
    Horwitz, Eric M.
    CANADIAN JOURNAL OF UROLOGY, 2016, 23 (06) : 8535 - 8545
  • [37] Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities
    Vashchenko, N
    Abrahamsson, PA
    EUROPEAN UROLOGY, 2005, 47 (02) : 147 - 155
  • [38] Prostate Cancer, Treatment Modalities and Complications: An Evaluation of the Scientific Literature
    Santos-Filho, Sebastiao David
    Missailids, Sotiris
    da Fonseca, Adenilson de Souza
    Bernardo-Filho, Mario
    BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY, 2008, 51 : 51 - 56
  • [39] Introducing ifosfamide in innovative treatment modalities
    Christian Dittrich
    Cancer Chemotherapy and Pharmacology, 2002, 49 : 1 - 3
  • [40] Introducing ifosfamide in innovative treatment modalities
    Dittrich, C
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (Suppl 1) : S1 - S3